21 August 2017
Visiongain’s new report The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography indicates that the SLE market will see over $570m in revenue in 2017.
The lead analyst of the report said:
“Systemic Lupus Erythematosus (SLE) is an autoimmune disease as the body's immune system mistakenly attacks healthy tissue. It affects the skin, joints, kidneys, brain, and other organs. Systemic Lupus Erythematosus is a chronic disease characterized with phases of worsening symptoms that alternate with periods of mild symptoms. Most people with Systemic Lupus Erythematosus lead a normal life with treatment. The term lupus used to identify a number of immune diseases that have homogenous clinical presentations and laboratory features, however Systemic Lupus Erythematosus is the most common type of lupus.
Currently, a lot of research activity is going on in the field of Systemic Lupus Erythematosus. There are around 60 molecules in active pipeline development. Many new therapies and mechanism of action are being tested in the pre-clinical stages or early stages like BTK, JAK inhibitors and T-cell modulator etc.
The current growth in Systemic Lupus Erythematosus market has also been fuelled by the therapies based on oral route of delivery. The diseases providing a greater benefit also commands a relatively higher price in the rare disease space.
The 152-page report contains 114 tables, charts and graphs that add visual analysis in order to explain developing trends within the Systemic Lupus Erythematosus market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading SLE submarkets, segmented by product, including forecasts for Atacicept, Benlysta, Anifrolumab, Lulizumab, Bisibimod, CellCept and Prograf. The SLE market is also segmented by Molecule Type, with forecasts for Small Molecules, Monoclonal Antibodies and Recombinant Proteins. The market is also segmented by pharmacological class, with forecasts for B-Cell Targeting Therapies, Interferon Receptor Antagonists, CD Antagonist Therapies and other Therapies for SLE.
The 152-page report offers market forecasts and analysis for 2 regional and 9 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 6 companies leading the SLE field in detail.
The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography report will be of value to anyone who wants to better understand the SLE market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the systemic lupus erythematosus therapy industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
02 September 2021
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.
24 August 2021
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
24 August 2021
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.